DASSAULT SYSTEMES SA ADR - DASTY STOCK NEWS

Dassault Systèmes announced the filing of its 2020 Universal Registration Document with the Autorité des marchés financiers on March 19, 2021. This document includes the Annual Financial Report, corporate governance report, and details about the share repurchase program. Investors can access the report on the company's website or request a hard copy at its headquarters in France. The filing demonstrates compliance with regulatory standards.

Dassault Systèmes, on March 18, 2021, announced a proposed annual cash dividend of €0.56 per share for the fiscal year 2020, to be voted on in the upcoming General Meeting of Shareholders on May 26, 2021. The ex-dividend date is set for May 28, 2021, with payments scheduled for June 1, 2021. CEO Bernard Charlès highlighted the strategic acquisition of MEDIDATA as pivotal during 2020, reinforcing the company's commitment to deleveraging and consistent dividend distribution.

On March 16, 2021, Dassault Systèmes disclosed details regarding the company's share repurchase program initiated on May 26, 2020. The buyback executed on March 8 and 9, 2021, involved a total of 62,348 shares at an average acquisition price ranging from €167.9747 to €169.0995. The repurchases were split between different markets, with 12,583 shares traded on XPAR and additional volumes on DXE. For further specifics, investors can access detailed transaction data on the company's investor relations website.

Dassault Systèmes has disclosed its stock repurchase activities from March 1 to March 5, 2021, as part of a buyback program approved at the General Meeting on May 26, 2020. During this period, a total of over 216,000 shares were repurchased across various markets including XPAR and DXE. The average acquisition price ranged from 168.74 to 171.93. For detailed trading data, investors can refer to the company's investor relations page.

Dassault Systèmes announced the total number of outstanding shares and voting rights as of February 28, 2021. The company reported 265,422,264 outstanding shares and 397,252,907 voting rights. This calculation includes shares with suspended voting rights, according to the regulations set by the Autorité des marchés financiers. Shareholders are advised to refer to the relevant articles for declarations related to crossing thresholds.

Dassault Systèmes disclosed its trading activities in its own shares on February 25 and 26, 2021, based on a buyback program approved at the General Meeting of Shareholders on May 26, 2020. The report details transactions by market and day, indicating that a total of 16,289 shares were purchased at an average price of €171.9886 on February 25, while 51,778 shares were acquired at €171.7171 on February 26. For more comprehensive transaction details, investors can visit the company's dedicated investor relations page.

Dassault Systèmes has announced its total number of outstanding shares and voting rights as of January 31, 2021. The company reports a total of 265,165,590 outstanding shares and 397,116,008 voting rights. This calculation includes shares with suspended voting rights, in compliance with the General Regulation of Autorité des marchés financiers. Shareholders are reminded to declare any crossing of threshold notifications to the company's Investor Relations Service.

Dassault Systèmes reported its fourth-quarter and full-year financial results for 2020, showcasing resilience despite the pandemic. Q4 total revenue increased 7% to €1.22 billion (IFRS), with non-IFRS total revenue of €1.22 billion up 5%. FY recurring revenue grew 27% to €3.2 billion, accounting for 80% of total software revenue. The company projects 2021 total revenue growth of 9% to 10%. EPS for the year was €1.86 (IFRS) and €3.77 (non-IFRS), with cash flow from operations rising 5% to €1.24 billion. Strong performance from MEDIDATA and ongoing R&D investments were highlighted.

Medidata, a Dassault Systèmes company, has expanded its partnership with Horizon Therapeutics to enhance clinical trial efficiencies across various therapeutic areas such as ophthalmology, rheumatology, and nephrology. The collaboration builds on a successful relationship that began in 2017. Medidata will provide Horizon with an extensive suite of clinical trial solutions, including the Medidata Rave Clinical Cloud and Intelligent Trials, which utilizes AI for data analytics and performance metrics. This partnership is expected to facilitate faster completion of clinical studies and improve overall trial management.